POTASSIUM CHANNEL INHIBITORS PHARMACODYNAMICS PATHWAY (PW:0000725)

View Ontology Report

Description

Nateglinide and repaglinide are used as blockers of the ATP-sensitive potassium channels (KATP) to promote insulin secretion and lower blood glucose levels in patients with type 2 diabetes mellitus (T2D). In response to elevated levels of circulating glucose; insulin is secreted from the pancreatic beta cells. This effect is counteracted by glucagon when the glucose levels are low - the two hormones act to maintain glucose homeostasis. The secr

Pathway Diagram:

Ariadne Genomics Inc. KATP KATP --+> insulin secretion pathway insulin secretion pathway repaglinide ---| KATP repaglinide nateglinide ---| KATP nateglinide insulin signaling pathway --+> insulin responsive facilitative sugar transporter mediated glucose transport pathway insulin secretion pathway --+> insulin signaling pathway insulin responsive facilitative sugar transporter mediated glucose transport pathway insulin released insulin signaling pathway ---> events mediated by insulin triggered pathways insulin signaling pathway ---> beta-cells events mediated by insulin triggered pathways events mediated by insulin triggered pathways glucose ---> glucose uptake: heart, skeletal muscle, adipose tissue glucose beta-cells events mediated by insulin triggered pathways insulin signaling pathway glucose uptake: heart, skeletal muscle, adipose tissue
GO TO:

Genes in Pathway:

show annotations for term's descendants       view all columns
potassium channel inhibitors pharmacodynamics pathway term browser
Symbol Object Name JBrowse Chr Start Stop Reference
G Abcc8 ATP binding cassette subfamily C member 8 JBrowse link 1 102,110,708 102,191,287 RGD:10402751
G Cacna1a calcium voltage-gated channel subunit alpha1 A JBrowse link 19 25,453,236 25,749,550 RGD:10402751
G Cacna2d2 calcium voltage-gated channel auxiliary subunit alpha2delta 2 JBrowse link 8 116,154,661 116,285,643 RGD:10402751
G Cacnb1 calcium voltage-gated channel auxiliary subunit beta 1 JBrowse link 10 85,954,138 85,974,764 RGD:10402751
G Ins2 insulin 2 JBrowse link 1 215,856,967 215,858,034 RGD:10402751
G Slc2a2 solute carrier family 2 member 2 JBrowse link 2 114,413,427 114,445,418 RGD:10402751

Additional Elements in Pathway:

(includes Gene Groups, Small Molecules, Other Pathways..etc.)
Object TypePathway ObjectPathway Object Description
Small Moleculenateglinidenateglinide
Small Moleculerepagliniderepaglinide

Pathway Gene Annotations

Disease Annotations Associated with Genes in the potassium channel inhibitors pharmacodynamics pathway
Disease TermsGene Symbols
Acute Kidney InjuryIns2
AdenomaIns2
AlbuminuriaIns2
Alzheimer DiseaseIns2
AtaxiaCacna1a , Cacna2d2
Bipolar DisorderIns2
Brain EdemaAbcc8
Brain InjuriesAbcc8
Breast NeoplasmsSlc2a2
Carcinoma, HepatocellularSlc2a2
Carcinoma, Pancreatic DuctalIns2 , Slc2a2
Cardiomyopathy, HypertrophicIns2
ChoreaCacna2d2
Colorectal NeoplasmsAbcc8
Congenital HyperinsulinismAbcc8
Developmental DisabilitiesCacna1a
Diabetes MellitusAbcc8 , Ins2
Diabetes Mellitus, ExperimentalSlc2a2
Diabetes Mellitus, Insulin-Dependent, 2Ins2
Diabetes Mellitus, Permanent NeonatalAbcc8 , Ins2
Diabetes Mellitus, Permanent Neonatal, with Neurologic FeaturesAbcc8
Diabetes Mellitus, Transient Neonatal, 2Abcc8
Diabetes Mellitus, Type 1Abcc8 , Ins2
Diabetes Mellitus, Type 2Abcc8 , Ins2 , Slc2a2
Diabetes, GestationalIns2
Diabetic CardiomyopathiesIns2
Diabetic KetoacidosisIns2
Diabetic NephropathiesIns2
Diabetic RetinopathyIns2
DysarthriaCacna1a
EdemaIns2
EndotoxemiaAbcc8
Epilepsy, AbsenceCacna1a , Cacna2d2
Epilepsy, GeneralizedCacna1a
Epilepsy, Temporal LobeCacna1a
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 42Cacna1a
Episodic Ataxia with NystagmusCacna1a
Exfoliation SyndromeCacna1a
Fanconi SyndromeSlc2a2
Fatty LiverIns2 , Slc2a2
Fetal Growth RetardationSlc2a2
GastrinomaSlc2a2
Genetic Diseases, InbornCacna1a
GlucagonomaSlc2a2
Glucose IntoleranceIns2
Glycogen Storage DiseaseSlc2a2
Heart ArrestAbcc8 , Ins2
Heart FailureIns2
Hemiplegic Migraine, Familial Type 1Cacna1a
HepatitisIns2
HyperglycemiaIns2
HyperinsulinismAbcc8 , Ins2
HyperkalemiaIns2
HyperplasiaAbcc8
HyperproinsulinemiaIns2
HypertensionAbcc8 , Ins2
HypertriglyceridemiaIns2
HyperuricemiaIns2
HypoglycemiaAbcc8 , Ins2
Hypoglycemia, Leucine-InducedAbcc8
HypokalemiaIns2
HypotensionIns2
Infarction, Middle Cerebral ArteryAbcc8
Infertility, FemaleCacna2d2
Insulin ResistanceIns2
InsulinomaIns2 , Slc2a2
Kidney Diseases, CysticIns2
Lewy Body DiseaseIns2
Liver Cirrhosis, ExperimentalIns2
Liver Failure, AcuteIns2
Maturity-Onset Diabetes of the YoungAbcc8 , Ins2
Maturity-Onset Diabetes of the Young, Type 1Ins2
Maturity-Onset Diabetes of the Young, Type 10Ins2
Memory DisordersIns2
Metabolic DiseasesIns2
Metabolic Syndrome XIns2
Migraine DisordersCacna1a
Migraine with AuraCacna1a
Migraine, Sporadic HemiplegicCacna1a
Muscular DiseasesIns2
Myocardial Reperfusion InjuryAbcc8
NecrosisAbcc8
Neural Tube DefectsIns2 , Slc2a2
Neurocognitive DisordersIns2
ObesityIns2
OsteoarthritisIns2
Pancreatic NeoplasmsIns2
PancreatitisIns2
Panic DisorderIns2
ParalysisIns2
ParesthesiaIns2
Parkinson DiseaseIns2
Parkinsonian DisordersAbcc8
Polycystic Ovary SyndromeIns2
Prostatic NeoplasmsIns2
Renal InsufficiencyIns2
RhabdomyolysisIns2
Sciatic NeuropathyAbcc8
Segawa Syndrome, Autosomal RecessiveIns2
SeizuresAbcc8 , Cacna1a , Ins2
Smith-Magenis SyndromeCacnb1
Spinal Cord InjuriesAbcc8
Spinocerebellar AtaxiasCacna1a
Status EpilepticusAbcc8
StrokeAbcc8
Subarachnoid HemorrhageAbcc8
Subarachnoid Hemorrhage, TraumaticAbcc8
TachycardiaIns2
Telomeric 22q13 Monosomy SyndromeIns2
Urinary Bladder DiseasesIns2
Ventricular Dysfunction, LeftIns2
Ventricular FibrillationIns2
Ventricular Outflow ObstructionIns2
Weight LossIns2
X-Linked Infantile Spasm SyndromeCacna2d2
Pathway Annotations Associated with Genes in the potassium channel inhibitors pharmacodynamics pathway
Pathway TermsGene Symbols
acebutolol pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
adrenergic beta receptor agonist and beta-blocker pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
aldosterone signaling pathwayIns2
alfentanil pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
altered insulin secretion pathwayAbcc8
altered insulin signaling pathwayIns2
amiodarone pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
amlodipine pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
arrhythmogenic right ventricular cardiomyopathy pathwayCacna2d2 , Cacnb1
atenolol pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
autophagy pathwayIns2
betaxolol pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
bisoprolol pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
bupivacaine pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
bupranolol drug pathwayAbcc8 , Cacna2d2 , Cacnb1
bupranolol pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
buprenorphine pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
calcium transport pathwayCacna1a , Cacnb1
calcium/calcium-mediated signaling pathwayCacna1a , Cacnb1
carvedilol pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
chloroprocaine pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
citalopram pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
cocaine pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
codeine and morphine pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
desipramine pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
diabetes pathwayAbcc8
dilated cardiomyopathy pathwayCacna2d2 , Cacnb1
diltiazem pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
diphenoxylate pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
disopyramide pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
dobutamine pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
escitalopram pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
esmolol pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
ethylmorphine pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
facilitative sugar transporter mediated glucose transport pathwaySlc2a2
fanconi syndrome pathwaySlc2a2
felodipine pharmacokinetics pathwayCacna2d2 , Cacnb1
fentanyl pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
flecainde pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
fluoxetine pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
forkhead class A signaling pathwayAbcc8 , Ins2 , Slc2a2
fosphenytoin pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
fructose-1,6-diphosphatase deficiency pathwaySlc2a2
gliclazide pharmacodynamics pathwayAbcc8 , Cacna1a , Cacna2d2 , Cacnb1 , Ins2 , Slc2a2
gluconeogenesis pathwaySlc2a2
glutamate signaling pathwayCacna1a
glyburide pharmacodynamics pathwayAbcc8 , Cacna1a , Cacna2d2 , Cacnb1 , Ins2 , Slc2a2
glycogen storage disease pathway, type IASlc2a2
glycogen storage disease pathway, type IBSlc2a2
glycogen storage disease pathway, type VIISlc2a2
glycolysis pathwaySlc2a2
heroin pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
hydrocodone pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
hydromorphone pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
hypertrophic cardiomyopathy pathwayCacna2d2 , Cacnb1
ibutilide pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
imipramine pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
insulin responsive facilitative sugar transporter mediated glucose transport pathwayIns2
insulin secretion pathwayAbcc8 , Cacna1a , Slc2a2
insulin signaling pathwayIns2
isoprenaline pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
isradipine pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
lactose degradation pathwaySlc2a2
levacetylmethadol pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
levobunolol pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
levobupivacaine phgarmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
levorphanol pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
lidocaine pharmacodynamics pathwayAbcc8 , Cacna1a , Cacna2d2 , Cacnb1
long term depressionCacna1a
maturity onset diabetes of the young pathwayIns2 , Slc2a2
mepivacaine pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
methadone pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
metoprolol pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
mexiletine pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
mitogen activated protein kinase signaling pathwayCacna1a , Cacna2d2 , Cacnb1
mTOR signaling pathwayIns2
nadolol pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
nalbuphine pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
naloxone pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
naltrexone pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
nebivolol pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
nicotine pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
nifedipine pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
nimodipine pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
nisoldipine pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
nitrendipine pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
oxybuprocaine pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
oxycodone pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
oxymorphone pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
penbutolol pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
pentazocine pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
phenytoin pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
phosphoenolpyruvate carboxykinase deficiency pathwaySlc2a2
pindolol pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
potassium channel inhibitors pharmacodynamics pathwayAbcc8 , Cacna1a , Cacna2d2 , Cacnb1 , Ins2 , Slc2a2
prilocaine pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
procainamide pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
procaine pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
propranolol pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
prostate cancer pathwayIns2
quinidine pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
remifentanil pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
ropivacaine pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
sotalol pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
timolol pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
tramadol pharmacodynamics pathwayCacna1a , Cacna2d2 , Cacnb1
trehalose degradation pathwaySlc2a2
triosephosphate isomerase deficiency pathwaySlc2a2
type 1 diabetes mellitus pathwayIns2
type 2 diabetes mellitus pathwayAbcc8 , Cacna1a , Ins2 , Slc2a2
verapamil pharmacodynamics pathwayAbcc8 , Cacna2d2 , Cacnb1
Phenotype Annotations Associated with Genes in the potassium channel inhibitors pharmacodynamics pathway
Phenotype TermsGene Symbols
abnormal gaitCacna1a

References Associated with the potassium channel inhibitors pharmacodynamics pathway:

Ontology Path Diagram:

paths to the root

Import into Pathway Studio: